Anosmia
Recent clinical, regulatory, research and industry developments relating to this disease.
Neurologic symptoms as a hallmark of glymphatic alteration in recovered patients with COVID-19.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials with recent milestones.
Clinical MilestonesViewHide
- 2026-07-01ClinicalA Single-Arm Study to Evaluate the Feasibility of CYR-064 Theophylline Nasal Spray for the Treatment of Parkinson's Disease Related Hyposmia and AnosmiaWithdrawn
- 2025-12-01ClinicalEfficacy of Adjunctive Sodium Citrate in Smell Retraining for People With Post-Acute Sequelae COVID-19 Olfactory DysfunctionPrimary completion
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes4
- Anosmia1
- Cognitive Dysfunction1
- COVID-191
- Glymphatic System1
Leading journals1
- BMC neurology1
Leading researchers6
- Choi KS1
- Kim M1
- Kim MS1
- Ko JS1
- Lee KH1
- Seo J1
Affiliations (unnormalised)4
- Kangbuk Samsung Hospital1
- Research Institute and Hospital of National Cancer Center1
- Seoul National University College of Medicine1
- Seoul National University of Science and Technology1
Reference
Authoritative identity, definition & identifiers.
Complete or severe loss of the subjective sense of smell. Loss of smell may be caused by many factors such as a cold, allergy, OLFACTORY NERVE DISEASES, viral RESPIRATORY TRACT INFECTIONS (e.g., COVID-19), aging and various neurological disorders (e.g., ALZHEIMER DISEASE).
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.